In this Between The Dose bonus episode of The Elevated Dose, I break down the new World Health Organization (WHO) guidelines on GLP-1 medications for obesity and what they mean for people actively using or considering GLP-1 therapy.

This episode explains, in plain language, how the WHO now formally recognizes obesity as a chronic, relapsing disease and endorses GLP-1 receptor agonists as legitimate long-term medical treatment for obesity, not shortcuts or failures of willpower.

We cover:

• ​ What the WHO guidelines actually say about GLP-1 medications for obesity
• ​ Why obesity is now classified as a chronic disease requiring ongoing care
• ​ How GLP-1 drugs like semaglutide and tirzepatide fit into long-term obesity treatment
• ​ Why weight regain after stopping GLP-1 medication is expected biology, not personal failure
• ​ The role of structure, routine, and behavioral support alongside GLP-1 therapy
• ​ The real barriers to GLP-1 access, including cost, insurance, and health-system limitations
• ​ What these guidelines mean for plateaus, slow progress, maintenance, and medication changes

This episode is especially relevant if you are:

• ​ On a GLP-1 and feeling stalled or discouraged
• ​ Navigating maintenance or worried about weight regain
• ​ Considering starting a GLP-1 medication for obesity
• ​ Recovering from years of dieting, medical gaslighting, or shame-based weight loss care

The WHO guidance validates what many people on GLP-1s already know from lived experience: obesity treatment is not about willpower; it’s about biology, access, and sustained medical support.

This episode is educational and based on lived experience. It is not medical advice. Always consult your healthcare provider regarding GLP-1 medications and obesity treatment.

Stay up to date on all things The Elevated Dose at www.theelevateddose.com

What happens after the weight loss works?

In this episode I dive into the part of GLP-1 care no one really prepares you for, the long game. The quiet exhaustion that can show up after success. The identity shift that happens when the urgency fades. And the emotional weight of realizing this isn’t a phase, a reset, or a short-term solution.

This conversation isn’t about side effects or starting a GLP-1. It’s about what comes next.

If you’ve been on a GLP-1 long enough for the excitement to wear off and you’re feeling tired even though things are “working”, this episode will help you understand why.

In this episode, we talk about:

• ​What journey fatigue really is (and what it isn’t)
• ​Why exhaustion often shows up after success
• ​The emotional reality of long-term GLP-1 care
• ​Maintenance anxiety and the fear of “messing it up”
• ​Identity shifts after weight loss
• ​Why gratitude and exhaustion can coexist
• ​Letting go of urgency and learning to live inside stability
• ​Why this isn’t a phase it’s care

Resources & Support

• ​Explore GLP-1 care and long-term provider support with Fridays: https://www.joinfridays.com/?via=carrie

Use code DOSE to save on your first month.

Stay Connected

Follow The Elevated Dose for grounded conversations about metabolic health, GLP-1 care, maintenance, and life beyond the scale.

Subscribe and leave a review if this episode resonated, it helps more people quietly navigating this phase find the show.

Share this episode with someone who did everything right… and is still tired.

Follow for more across social media at www.theelevateddose.com

This isn’t a phase.

It’s the long game.